Paris-based biotech company Generare has made significant strides in drug discovery, claiming to have identified more than 200 novel small molecules in 2025—outpacing the entire field combined. This achievement highlights a critical issue in the industry: the reliance on stale chemical libraries and repetitive data sets, which hinders true innovation. Generare aims to address this by building a proprietary dataset of previously untapped molecular chemistry derived from microbial genomes, which could serve as a foundation for future drug development.

The significance of Generare’s approach lies in its potential to transform the landscape of drug discovery. By leveraging microbial genetic information, the company is uncovering molecules that have remained hidden due to a lack of efficient testing methods. As CEO Guillaume Vandenesch notes, the real bottleneck in drug discovery is not the algorithms but the absence of genuinely novel, high-quality molecular data. This new focus on evolution-derived molecules could lead to innovative therapeutic candidates, particularly in the context of aging-related diseases, where traditional drug discovery methods have often fallen short.

The implications of Generare’s model extend beyond its immediate discoveries. As the company scales its molecular discovery engine with plans to increase its output tenfold by 2027, it underscores the need for new mechanisms of action in longevity research. Access to these novel compounds could shift the paradigm from merely optimizing existing therapies to exploring entirely new pathways for intervention. For longevity biotech, this means that the future of effective treatments for age-related conditions may hinge on broadening the search for biological innovations, rather than relying solely on established methodologies.

Source: longevity.technology